Holly A. Swain Ewald, PhD

All articles by Holly A. Swain Ewald, PhD

feature

The FDA recommended the approval of CTL019 chimeric antigen receptor (CAR) T cell therapy for acute lymphoblastic leukemia (ALL).

Paul W. Ewald

September 5, 2017